<DOC>
	<DOCNO>NCT02914522</DOCNO>
	<brief_summary>The primary objective study evaluate safety efficacy filgotinib induction maintenance treatment moderately severely active ulcerative colitis ( UC ) participants biologic-naive biologic-experienced . Participants complete study , meet protocol response remission criterion Week 10 option enter separate , long-term extension ( LTE ) study ( Gilead Study GS-US-418-3899 ) .</brief_summary>
	<brief_title>Filgotinib Induction Maintenance Remission Adults With Moderately Severely Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Key Males nonpregnant , nonlactating female , age 18 75 year , inclusive base date screen visit Documented diagnosis UC least 6 month AND minimum disease extent 15 cm anal verge . Documentation include endoscopic histopathologic evidence UC . A surveillance colonoscopy require screening individual history UC 8 year , one perform prior 24 month Moderately severely active UC Previously demonstrate inadequate clinical response , loss response , intolerance least 1 follow agent : corticosteroid , immunomodulators , tumor necrosis factor alpha ( TNFa ) antagonists , vedolizumab Key Presence Crohn 's disease , indeterminate colitis , ischemic colitis , fulminant colitis , ulcerative proctitis , toxic megacolon Active tuberculosis ( TB ) history latent TB treat Use concomitant prohibit medication describe protocol Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>